Tencentriq was granted accelerated approval for use in combination with paclitaxel protein-bound for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer whose tumors express PD-L1 on March 8, 2019.
The indication is approved under accelerated approval based on progression-free survival and continued approval may be contingent on verification and description of clinical benefit in confirmatory trials, according to the FDA.
CSI is one of the first reference laboratories to offer the new companion test.
The new assay is used to determine PD-L1 stained tumor-infiltrating immune cells of any intensity covering ≥ 1% of the tumor area.
CSI Laboratories is a specialised cancer diagnostics laboratory focused specifically on meeting the unique needs and challenges of pathologists and community hospitals.
CSI Laboratories offers flow cytometry, cytogenetic analysis, fluorescence in-situ hybridization, immunohistochemistry, molecular genetics, and consultations in the areas of hematopathology and surgical pathology.
CSI Laboratories is a CLIA-certified and CAP-accredited laboratory located in Alpharetta, GA.
CSI Laboratories is independently owned and operated by medical professionals and has provided expert diagnostic testing to pathologists across the United States since 1997.
Klotho Neurosciences receives FDA Orphan Drug Designation for ALS gene therapy candidate
Zhimeng Biopharma's CB03-154 ALS Phase 2/3 study receives Chinese clinical trial approval
Taiho Oncology and Taiho Pharmaceutical's INQOVI/venetoclax combination sNDA accepted by US FDA
Alvotech strengthens biosimilar operations with acquisition of Ivers-Lee Group
Adcentrx Therapeutics' ADRX-0405 granted US FDA orphan drug designation
Orsini named KalVista's specialty pharmacy partner for EKTERLY (sebetralstat)
KalVista secures FDA approval for EKTERLY, first oral on-demand HAE treatment
Alcon to acquire LumiThera and its FDA-authorised photobiomodulation device for dry AMD treatment
Akeso's bispecific ADC (Trop2/Nectin4 ADC) enters clinical trials